Diagnosis, prevention, medicine

On May 26, 2021, Diaprof-Med will take part in the Scientific and Practical Conference with International Participation "Status and...

DIAPROF MED has successfully passed a recertification audit in order to confirm the conformity of products bearing the CE mark with the...

(USREOU code 24265186, location: 03113, Kyiv, 68/1 Peremohy Ave., office 62) (hereinafter - the Company) announces the convening of the...

On October 28, 2020, at 13:00, are being briefing developers of the candidate for the SARS-CoV-2 vaccine. (COVID 19) The briefing will be...

September 23, 2020 at the Scientific and Practical Conference with International Participation "Efficiency, Quality and Availability of...

On September 18, 2020, the company launched and operated a medical device for in vitro diagnostics - DIA®-SARS-CoV-2-Ag Enzyme-linked...

Parallel testing of ninety‐two plasma samples of COVID‐19 convalescent donors, detected positive for IgG in the Abbott Architect...

Information on the decision to pre-consent to major transactions

Since April 13, 2020, the company has put into operation and operation a medical device for in vitro diagnostics - DIA®-SARS-CoV-2-NP-IgG...

Private Joint Stock Company Scientific-Production Company “DIAPROPH-MED” (USREOU code 24265186, location: Kyiv 03113, 68/1 Peremohy Ave.,...

We offer new test kits for the diagnosis of Epstein-Barr virus: DIA®-EBV-VCA-IgG Enzyme immunoassay for the qualitative and...